Brand Name :
Ponstel
Synonyms :
mefenamic acid
Class :
Nonsteroidal Anti-Inflammatory Drugs
Dosage Forms & Strengths
Capsule
250mg
Indicated for Primary Dysmenorrhea:
Initial dose: 500mg orally once then 250mg orally four times a day whenever necessary
Do not exceed for more than three days
Initial dose: 500mg once orally, then 250mg orally four times daily whenever necessary
Do not exceed for more than seven days
Indicated for Primary Dysmenorrhea:
<14 years: Not recommended
>14 years: Initial dose- 500mg orally once, then 250mg orally four times a day whenever necessary
Do not exceed more than three days
Dosage Forms & Strengths
Capsule
250mg
<14 years: Not recommended
>14 years: Initial dose: 500mg orally once, then 250mg orally four times a day whenever necessary
Do not exceed for more than seven days
Initial dose: 500mg orally once then 250mg orally four times a day whenever necessary
Do not exceed for more than seven days
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may decrease the diuretic effect of nonsteroidal anti-inflammatory agents
may decrease the diuretic effect of nonsteroidal anti-inflammatory agents
may decrease the diuretic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
choline magnesium trisalicylate
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may decrease the diagnostic effect when combined with metyrapone
triamcinolone acetonide/nystatin
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
methenamine/sodium salicylate/benzoic acid
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the diagnostic effect of nonsteroidal anti-inflammatory agents
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
Hormonal Contraceptives increase the effect of thrombogenesis of tranexamic acid
Could potentially reduce the concentration serum of hormonal contraceptives
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may decrease the excretion of nonsteroidal anti-inflammatory agents
may decrease the excretion of nonsteroidal anti-inflammatory agents
may decrease the excretion of nonsteroidal anti-inflammatory agents
may decrease the excretion of nonsteroidal anti-inflammatory agents
may decrease the excretion of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the anti-coagulant effect of antiplatelet agents
may increase the anti-coagulant effect of antiplatelet agents
may increase the anti-coagulant effect of antiplatelet agents
may increase the anti-coagulant effect of antiplatelet agents
may increase the anti-coagulant effect of antiplatelet agents
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the absorption of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
spironolactone and hydrochlorothiazide
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of antiplatelet agents
may increase the antiplatelet effect of antiplatelet agents
may increase the antiplatelet effect of antiplatelet agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
Combining mefenamic acid with pranlukast may cause a reduction in the mefenamic acid’s metabolism
when bromazepam and mefenamic acid are used together, there is a potential reduction in the bromazepam's metabolism
when both drugs are combined, the risk or severity of adverse effects increases
glycopyrrolate inhaled and formoterol
decreases the serum potassium levels
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
The concentration serum of flibanserin may be intensified by hormonal contraceptive
may enhance the renal tubular clearance for anionic drug competition
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
mycophenolate could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Actions and Spectrum:
Frequency defined
>10%
Borderline elevations of one or more LFTs (<15%)
1-10%
Anorexia
Nausea
Gastritis
Constipation
Steatorrhea
Abdominal pain
Diarrhea
Pyrosis
Flatulence
<1%
Eosinophilia
Agranulocytosis
Bone marrow hypoplasia
Leukopenia
Thrombocytopenic purpura
Pancytopenia
Black box warning:
Contraindications/caution:
Contraindications:
The contraindications of mefenamic acid include:
Caution:
Several cautions should be considered when using mefenamic acid, including: